DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles

Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pregnancy Outcome After In Vitro Fertilization (IVF)

Intervention: In vitro fertilization (Other)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Universitair Ziekenhuis Brussel

Official(s) and/or principal investigator(s):
Basil Tarlatzis, MD, Study Chair, Affiliation: BioGenesis

Summary

The aim is to explore whether the incidence of progesterone rise in the late follicular phase differs between GnRH-agonist and GnRH-antagonist protocols for IVF and whether this has an impact on the probability of pregnancy achievement.

Clinical Details

Official title: Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Incidence of late progesterone rise on the day of HCG triggering

Secondary outcome: Clinical pregnancy rate Delivery rate

Detailed description: In view of the current debate concerning possible differences in efficacy between the two GnRH analogues, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH-agonist is used as compared to GnRH-antagonist and if so to what extend does the progesterone rise have an impact on the probability of achieving a pregnancy.

Eligibility

Minimum age: 21 Years. Maximum age: 39 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- age < 39

- follicle-stimulating hormone (FSH) < 12

- gonadotropin dose 100-300IU

Exclusion Criteria:

- endometriosis

- known endocrine disorder

- blood analyzed in another laboratory

Locations and Contacts

Biogenesis, Thessaloniki, Pylaia 55536, Greece
Additional Information

Related publications:

Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, Van Steirteghem A, Devroey P. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril. 2009 Mar;91(3):949-52. Epub 2007 Jun 6.

Starting date: January 2007
Last updated: September 14, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017